Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
KERX [NASD]
Keryx Biopharmaceuticals Inc.
Index- P/E- EPS (ttm)-0.80 Insider Own2.00% Shs Outstand91.82M Perf Week10.10%
Market Cap1.32B Forward P/E- EPS next Y-0.36 Insider Trans-7.18% Shs Float89.91M Perf Month-20.06%
Income-69.30M PEG- EPS next Q-0.27 Inst Own76.10% Short Float24.37% Perf Quarter-10.40%
Sales10.00M P/S132.13 EPS this Y-65.70% Inst Trans0.55% Short Ratio9.18 Perf Half Y-15.50%
Book/sh1.36 P/B10.58 EPS next Y59.60% ROA-63.10% Target Price23.42 Perf Year38.50%
Cash/sh1.49 P/C9.64 EPS next 5Y30.00% ROE-74.50% 52W Range8.61 - 18.48 Perf YTD11.12%
Dividend- P/FCF- EPS past 5Y13.20% ROI-103.70% 52W High-22.13% Beta3.17
Dividend %- Quick Ratio7.50 Sales past 5Y42.30% Gross Margin- 52W Low67.13% ATR0.71
Employees88 Current Ratio7.50 Sales Q/Q- Oper. Margin- RSI (14)49.37 Volatility4.18% 5.25%
OptionableYes Debt/Eq0.00 EPS Q/Q-71.40% Profit Margin- Rel Volume0.98 Prev Close13.75
ShortableYes LT Debt/Eq0.00 EarningsNov 03 BMO Payout- Avg Volume2.39M Price14.39
Recom1.90 SMA200.31% SMA50-6.64% SMA200-2.34% Volume2,338,700 Change4.65%
22-Sep-14Resumed Oppenheimer Outperform $22
08-Sep-14Downgrade FBR Capital Mkt Perform → Underperform
14-Aug-14Initiated FBR Capital Mkt Perform $16
23-May-14Reiterated H.C. Wainwright Buy $19
12-May-14Reiterated MLV & Co Buy $27 → $21
04-Apr-14Reiterated Ladenburg Thalmann Buy $24 → $30
02-Apr-14Reiterated Mizuho Buy $25 → $34
01-Apr-14Reiterated Oppenheimer Outperform $20 → $22
21-Mar-14Initiated Mizuho Buy $25
14-Mar-14Reiterated Stifel Buy $17 → $19
27-Jan-14Reiterated Maxim Group Buy $16 → $25
17-Oct-13Reiterated Ladenburg Thalmann Buy $15 → $19
01-Aug-13Reiterated Maxim Group Buy $9 → $12
29-Jan-13Reiterated Stifel Nicolaus Buy $4 → $13
29-Jan-13Reiterated MLV & Co Buy $5 → $15
29-Jan-13Reiterated Ladenburg Thalmann Buy $5 → $15
29-Jan-13Reiterated Burrill Institutional Research Mkt Outperform $6 → $11
28-Jan-13Reiterated Maxim Group Buy $4 → $9
13-Dec-12Initiated Maxim Group Buy $4
13-Nov-12Initiated Burrill Institutional Research Mkt Outperform $6
01-Oct-14 07:30AM  Keryx Biopharmaceuticals Announces Issuance of a New U.S. Patent for Ferric Citrate Covering Orally Administrable Forms GlobeNewswire
29-Sep-14 07:30AM  Keryx Biopharmaceuticals Initiates Pivotal Phase 3 Study of Ferric Citrate for the Treatment of Iron Deficiency Anemia in Patients With Non-Dialysis Dependent Chronic Kidney Disease GlobeNewswire
11-Sep-14 10:30AM  Insider Trading Alert - DVA, DATA And KERX Traded By Insiders at TheStreet
07:59AM  The Zacks Analyst Blog Highlights: AbbVie, Infinity Pharmaceuticals, Keryx Biopharmaceuticals, Gilead and Amgen Zacks
08-Sep-14 05:05PM  Keryx Falls after Ferric Citrate's Approval with Warnings Zacks -11.17%
04:09PM  Keryx CEO says FDA warning label for drug is 'grossly misunderstood' at MarketWatch
01:11PM  [$$] Keryx's FDA Approval a Mixed Bag at Barrons.com
11:25AM  Why Keryx Biopharmaceuticals (KERX) Stock Is Falling Today at TheStreet
07:09AM  Keryx Biopharmaceuticals (KERX) Crumbles: Stock Falls by 5.5% Zacks
07:00AM  Keryx Bear Case Bolstered by Less-Than-Zippy 'Zerenex' Label at TheStreet
06:20AM  Keryx Biopharma downgraded by FBR Capital Briefing.com
06-Sep-14 09:01AM  Correction: Keryx-Drug Approval story AP
05-Sep-14 08:59PM  Warnings Issued for Keryx Dialysis Drug at New York Times -5.45%
05:08PM  FDA approves Keryx's kidney drug with warnings, shares fall Reuters
05:03PM  KERYX BIOPHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
04:00PM  Keryx Biopharmaceuticals, Inc. to Present at the Rodman & Renshaw 16th Annual Global Investment Conference GlobeNewswire
03:05PM  Keryx Finds Out That Not All FDA Approvals Are Great Wins at 24/7 Wall St.
02:49PM  Infoblox Inc. (BLOX) Climbs On Earnings at TheStreet
12:36PM  Infoblox Inc Gains On Upbeat Results; The Gap Inc. Shares Decline Benzinga
12:00PM  Keryx Biopharmaceuticals Inc Conference Call to discuss the approval of Ferric Citrate scheduled for 12:00 pm ET today CCBN
11:28AM  Keryx Biopharma gets U.S. approval for kidney drug Reuters
11:17AM  Keryx Biopharmaceuticals Receives FDA Approval of Ferric Citrate, a New, Oral Iron-Based Treatment for Dialysis Patients With Hyperphosphatemia GlobeNewswire
26-Aug-14 09:50AM  Your September Biotech Back-to-School Calendar at TheStreet
06:39AM  Keryx Biopharmaceuticals (KERX) in Focus: Stock Adds 8.4% in Session Zacks
25-Aug-14 01:32PM  Barbarian At The Gate: Keryx Biopharmaceuticals (KERX) at TheStreet +8.43%
15-Aug-14 01:04PM  KERYX BIOPHARMACEUTICALS INC Financials EDGAR Online Financials
14-Aug-14 07:02PM  Seth Klarman's The Baupost Group Buys eBay, SunEdison Semiconductor, Keryx Biopharmaceuticals, ... Gurufocus
08-Aug-14 09:24AM  H.C. Wainwright & Co. Believes Keryx Biopharmaceuticals Remains Undervalued Benzinga
07-Aug-14 08:00AM  Keryx Biopharmaceuticals Inc Earnings Call scheduled for 8:00 am ET today CCBN
07:50AM  KERYX BIOPHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements EDGAR Online
07:07AM  Q2 2014 Keryx Biopharmaceuticals, Inc. Earnings Release - Before Market Open CCBN
07:00AM  Keryx Biopharmaceuticals, Inc. Announces Second Quarter and Six Month 2014 Financial Results GlobeNewswire
05-Aug-14 08:00AM  Keryx Biopharmaceuticals, Inc. to Host Conference Call on Second Quarter 2014 Financial Results GlobeNewswire
24-Jul-14 05:00PM  Keryx drug improves phosphorus, iron in kidney patients -trial Reuters
05:00PM  Zerenex(TM) (Ferric Citrate) Long-Term Phase 3 Study Results Published in the Journal of the American Society of Nephrology GlobeNewswire
22-Jul-14 08:46AM  Should You Join This Major Hedge Fund in Buying Keryx Stock? at Motley Fool
24-Jun-14 05:01PM  KERYX BIOPHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders EDGAR Online
08:00AM  Keryx Biopharmaceuticals: Baupost Group's New Position Suggests A Possible Takeout And 100%+ Gains at Seeking Alpha
18-Jun-14 08:30AM  Keryx Biopharmaceuticals Announces Issuance of Two U.S. Patents for Zerenex(TM) Covering Orally Administrable Forms of Ferric Citrate GlobeNewswire
17-Jun-14 04:30PM  Keryx Biopharmaceuticals, Inc. to Present at the 9th Annual JMP Securities Healthcare Conference GlobeNewswire
06-Jun-14 06:02PM  4 Reasons Why Wall Street Hates Keryx Biopharmaceuticals Inc. at Motley Fool
09:00AM  The Baupost Group buys a new position in Keryx Biopharmaceuticals Market Realist
05-Jun-14 12:33PM  Must-know highlights of the Baupost Groups 1Q 2014 positions Market Realist
08:30AM  Keryx Biopharmaceuticals, Inc. to Present at the 35th Annual Goldman Sachs Global Healthcare Conference GlobeNewswire
29-May-14 07:34PM  Keryx Biopharma: Approval Delay Does Not Change Zerenex Prospects Or Differentiation at Seeking Alpha
23-May-14 11:00AM  Options with decreasing implied volatility at theflyonthewall.com
08:48AM  Today's Top Health Care Stocks to Watch: PTC Therapeutics, Inovio Pharmaceuticals and Keryx Biopharmaceuticals at Motley Fool
07:30AM  Keryx PDUFA extension creates buying opportunity, says Oppenheimer at theflyonthewall.com
22-May-14 05:21PM  KERYX BIOPHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
04:33PM  Keryx announces FDA extends PDUFA date for Zerenex at theflyonthewall.com
04:30PM  Keryx Receives Notification of PDUFA Date Extension for Zerenex(TM) GlobeNewswire
19-May-14 05:35PM  Biotech Tweet of the Week: Investing in Moldy Pizza at Motley Fool
11:40AM  Seth Klarman's Baupost: Investment Changes During The First Quarter at Seeking Alpha
11:20AM  Deerfield reports 4.87% passive stake in Keryx at theflyonthewall.com
12-May-14 06:43PM  Baupost's Seth Klarman Takes 10% Stake in Keryx Biopharmaceuticals Gurufocus +5.20%
09:22AM  2014 FDA Drug Approval Calendar at TheStreet
08:12AM  UPDATE: MLV & Co Reiterates On Keryx Biopharmaceuticals On Increased Risk Benzinga
09-May-14 04:03PM  The Baupost Group reports 10.07% passive stake in Keryx at theflyonthewall.com
08-May-14 03:42PM  Why Keryx Biopharmaceuticals (KERX) Stock Is Down Today at TheStreet -13.72%
02:31PM  Keryx Biopharmaceuticals' (KERX) CEO Ron Bentsur on Q1 2014 Results - Earnings Call Transcript at Seeking Alpha
01:10PM  Why Keryx Biopharmaceuticals, Inc. Shares Swooned at Motley Fool
12:16PM  Keryx weakness a buying opportunity, says Brean Capital at theflyonthewall.com
11:31AM  Keryx June volatility elevated into PDUFA at theflyonthewall.com
08:00AM  Keryx Biopharmaceuticals, Inc. Earnings Call scheduled for 8:00 am ET today CCBN
07:22AM  Keryx reports Q1 EPS (15c), consensus (8c) at theflyonthewall.com
07:18AM  KERYX BIOPHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition EDGAR Online
07:07AM  Q1 2014 Keryx Biopharmaceuticals, Inc. Earnings Release - Time Not Supplied CCBN
07:00AM  Keryx Biopharmaceuticals, Inc. Announces First Quarter 2014 Financial Results GlobeNewswire
06-May-14 08:00AM  Keryx Biopharmaceuticals Announces Opening of Boston Office GlobeNewswire
05-May-14 04:30PM  Keryx Biopharmaceuticals, Inc. to Host Conference Call on First Quarter 2014 Financial Results GlobeNewswire
01-May-14 10:05AM  Cytokinetics Binary Failure Provides Solid Opportunity at Seeking Alpha
10:05AM  Cytokinetics Binary Failure Provides Solid Buying Opportunity at Seeking Alpha
25-Apr-14 11:56AM  Glenn R. Mattes, the President, CEO and Director of Arno Therapeutics, Inc. (ARNI), Interviews with The Wall Street Transcript Wall Street Transcript
23-Apr-14 04:32PM  KERYX BIOPHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
16-Apr-14 10:45AM  Keryx Biopharmaceuticals: Is The High Valuation Justified? at Seeking Alpha
15-Apr-14 08:30AM  Keryx Biopharmaceuticals Strengthens Leadership Team With Key Additions in Sales, Corporate Development and Legal GlobeNewswire
11-Apr-14 09:00AM  Reviewing An Aggressive Strategy In A Volatile Market at Forbes
09-Apr-14 08:30AM  Keryx Biopharmaceuticals Announces Zerenex(TM) (Ferric Citrate Coordination Complex) Phase 2 Results in Non-Dialysis Dependent Chronic Kidney Disease Selected as a Late Breaking Oral Presentation at the Upcoming National Kidney Foundation 2 GlobeNewswire
Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of renal disease in the United States. It is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes. The company has completed Phase III clinical program for Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with chronic kidney disease on dialysis. Zerenex has also completed a Phase II study for the management of elevated serum phosphorus levels and iron deficiency anemia in patients with stages three to five non-dialysis dependent chronic kidney disease. The company has sublicense agreements with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of Zerenex in Japan. It also has strategic alliances with Panion & BF Biotech, Inc. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BENTSUR RONChief Executive OfficerSep 12Sale14.2450,000712,000826,815Sep 12 08:30 PM
Oliviero James F IIIChief Financial OfficerSep 08Sale15.88144,2372,290,484156,039Sep 10 08:00 PM
BENTSUR RONChief Executive OfficerJul 07Sale15.751,78828,161876,815Jul 09 08:00 PM
Oliviero James F IIIChief Financial OfficerJul 07Sale15.752,05432,351300,276Jul 09 08:00 PM
Oliviero James F IIIChief Financial OfficerApr 03Sale16.462,08734,352302,330Apr 07 07:24 PM
BENTSUR RONChief Executive OfficerApr 03Sale16.461,81629,891878,603Apr 07 07:18 PM
Oliviero James F IIIChief Financial OfficerMar 21Sale15.1113,444203,139304,417Mar 21 09:30 PM
Oliviero James F IIIChief Financial OfficerMar 20Sale15.04125,0001,880,000317,861Mar 21 09:30 PM
Oliviero James F IIIChief Financial OfficerMar 19Option Exercise3.54104,039367,812596,900Mar 21 09:30 PM
Oliviero James F IIIChief Financial OfficerMar 19Sale15.23154,0392,346,014442,861Mar 21 09:30 PM
Oliviero James F IIIChief Financial OfficerJan 03Sale12.576,30979,304492,861Jan 06 08:00 PM
BENTSUR RONChief Executive OfficerJan 03Sale12.575,25766,080880,419Jan 06 08:00 PM
Oliviero James F IIIChief Financial OfficerDec 30Option Exercise4.5930,000137,700506,429Dec 31 08:00 PM
Oliviero James F IIIChief Financial OfficerDec 30Sale12.6379,5001,003,890476,429Dec 31 08:00 PM
Oliviero James F IIIChief Financial OfficerDec 27Sale12.6830,000380,400525,929Dec 31 08:00 PM
Oliviero James F IIIChief Financial OfficerOct 03Sale10.251,47515,119555,929Oct 07 07:04 PM
BENTSUR RONChief Executive OfficerOct 03Sale10.252,50525,676459,065Oct 07 07:02 PM